Keros Therapeutics/KROS

$56.75

2.82%
-
1D1W1MYTD1YMAX

About Keros Therapeutics

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its second product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its third product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.

Ticker

KROS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Jasbir Seehra

Employees

136

Headquarters

Lexington, United States

KROS Metrics

BasicAdvanced
$2.01B
Market cap
-
P/E ratio
-$5.19
EPS
1.33
Beta
-
Dividend rate
$2.01B
1.32869
$73.00
$27.02
372.71K
14.249
-45.21%
-50.19%
-48.12%
13,292.13
5.346
6.042
-25.21%

What the Analysts think about KROS

Analyst Ratings

Majority rating from 10 analysts.
Buy

Price Targets

Average projection from 8 analysts.
56.62% upside
High $105.00
Low $77.00
$56.75
Current price
$88.88
Average price target

KROS Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-40,200% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$100K
∞%
Net income
$-40.2M
2.03%
Profit margin
-40,200%
-∞%

KROS Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 2.51%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$1.26
-$1.27
-$1.33
-$1.34
-
Expected
-$1.12
-$1.34
-$1.35
-$1.37
-$1.35
Surprise
12.21%
-5.12%
-1.31%
-2.51%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Keros Therapeutics stock?

Keros Therapeutics (KROS) has a market cap of $2.01B as of April 25, 2024.

What is the P/E ratio for Keros Therapeutics stock?

The price to earnings (P/E) ratio for Keros Therapeutics (KROS) stock is 0 as of April 25, 2024.

Does Keros Therapeutics stock pay dividends?

No, Keros Therapeutics (KROS) stock does not pay dividends to its shareholders as of April 25, 2024.

When is the next Keros Therapeutics dividend payment date?

Keros Therapeutics (KROS) stock does not pay dividends to its shareholders.

What is the beta indicator for Keros Therapeutics?

Keros Therapeutics (KROS) has a beta rating of 1.33. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Keros Therapeutics stock price target?

The target price for Keros Therapeutics (KROS) stock is $88.88, which is 58.04% above the current price of $56.24. This is an average based on projections from 8 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Keros Therapeutics stock

Buy or sell Keros Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing